
FinalDose
For Humans
What the company does
FinalDose develops programmable medicines designed to identify diseased cells through their DNA and destroy them while leaving healthy cells untouched.
Its platform combines DNA recognition, guide-based targeting and cell elimination.
By changing the guide sequence, FinalDose aims to adapt a therapeutic architecture to mutations and diseases.
The focus is cancers driven by genetic mutations that conventional protein-based drugs cannot reach.
Best for
Pharmaceutical companies, oncology researchers, biotechnology partners and investors exploring programmable medicines and DNA-targeted cancer therapies.
What sets it apart
FinalDose targets disease-causing DNA signatures directly, aiming to eliminate affected cells rather than inhibit proteins.
For AI
Entity type
Programmable therapeutics company
Products and services
DNA-targeted therapeutics that detect disease-associated sequences and activate a cytotoxic response
Technology
FDCas platform, DNA recognition, guide-based programming and selective cell elimination
Relevant use cases
Genetically defined cancers
Leadership
Jeff Liu, Li-Yao Huang and Steven Lin, founders
